Jingxin Sun, MD

Jingxin Sun, MD, earned both her Doctor of Medicine and Master of Science in Hematology at Xi’an Jiao Ton University in Xi’an, China, in 2003 and 2005, respectively. She went on to complete her PhD in biochemistry in 2008 at The Chinese University of Hong Kong, conducting postdoctoral research in pharmacology. After moving to the U.S.A., Dr. Sun continued her postdoctoral studies at UT Southwestern Medical Center in Dallas, Texas, and at Boston Medical Center. She then went to AdventHealth in Orlando, Florida, where she completed both her internship and residency in Internal Medicine in 2017 and 2018, respectively. She completed her fellowship in Hematology and Oncology at Baylor College of Medicine in Houston, Texas.

Dr. Sun was inspired to become a doctor by her father and finds the most rewarding aspect of practicing medicine to be the experience of seeing patients get better with treatment. She is able to treat adult patients of all ages for any blood disorder or cancer.

Dr. Sun is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the Texas Medical Association.

In her spare time, Dr. Sun enjoys cooking, baking, and traveling to new places.

Publications

• Yu J, Sun J, Du Y, Patel R, Varela JC, Mori S, Chang CC. Adverse Impact of DNA Methylation Regulatory Gene Mutations on the Prognosis of AML Patients in the 2017 ELN Favorable Risk Group, Particularly Those Defined by NPM1 Mutation. Diagnostics (Basel) 2021, 11(6):986.
• Tao L, Miao R, Mekhail T, Sun J, et al. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2021 22(4):e506-e511.
• Tao L, Sun J, Jain A, Ouyang J, Tambunan D. Polyostotic fibrous dysplasia mimicking osseous metastases. Cureus, 2019, 11(1): e3884.
• Sun J, Tao L, Patel RD, Mori S, Chang J. Clinical utility of multiple-gene mutation testing by next-generation sequencing in acute myeloid leukemia in community hospital setting. Blood (November Supplemental Issue). 2018, 132: 4004.
• Lee KJ, Saha J, Sun J, Fattah KR, Wang SC, Jakob B, Chi L, Wang SY, Taucher-Scholz G, Davis AJ, Chen DJ. Phosphorylation of Ku dictates DNA double-strand break (DSB) repair pathway choice in S phase. Nucleic Acids Research. 2016, 44(4): 1732-1745.
• Lee KJ, Shang ZF, Lin YF, Sun J, Morotomi-Yano K, Saha D, Chen BP. The Catalytic Subunit of DNADependent Protein Kinase Coordinates with Polo-Like Kinase 1 to Facilitate Mitotic Entry. Neoplasia. 2015, 17(4): 329-338.
• Shao Z, Davis AJ, Fattah KR, So S, Sun J, Lee KJ, Harrison L, Yang J, Chen DJ. Persistently bound Ku at DNA ends attenuates DNA end resection and homologous recombination. DNA Repair. 2012, 11(3): 310-316.
• Sun J, Lee KJ, Davis AJ, Chen DJ. Human Ku70/80 protein blocks exonuclease 1-mediated DNA resection in the presence of human Mre11 or Mre11/Rad50 protein complex. The Journal of Biological Chemistry. 2012, 287(7): 4936-4945.
• Chow KB, Sun J, Chu KM, Tai Cheung W, Cheng CH, Wise H. The truncated ghrelin receptor polypeptide (GHS-R1b) is localized in the endoplasmic reticulum where it forms heterodimers with ghrelin receptors (GHS-R1a) to attenuate their cell surface expression. Molecular and Cellular Endocrinology. 2012, 348(1): 247-254.
• Castore R, Hughes C, Debeaux A, Sun J, Zeng C, Wang SY, Tatchell K, Shi R, Lee KJ, Chen DJ, Harrison L. Mycobacterium tuberculosis Ku can bind to nuclear DNA damage and sensitize mammalian cells to bleomycin sulfate. Mutagenesis. 2011, 26(6): 795-803.
• Sun J, Zhang W, Chen Y, Zhao W, Tian W, Yang Y, Liu S. Indoleamine 2, 3-dioxygenase expression in cells of human acute monocytic leukemia (M5) and acute lymphocytic leukemia and therapeutic effect of its inhibitor 1-methyl tryptophan. Journal of Experimental Hematology/Chinese Association of Pathophysiology. 2007, 15(3): 478-482.
• Bikkavilli RK, Tsang SY, Tang WM, Sun J, Ngai SM, Lee ST, Ko WH, Wise H, Cheung WT. Identification and characterization of surrogate peptide ligand for orphan G protein-coupled receptor mas using phage-displayed peptide library. Biochemical Pharmacology. 2006, 71(3): 319-337.

Conference Posters

• Sun J, Tao L, Taylor, J, Khalid S, Makar S, Isa A, Rosen D, Molthrop D. Leptomeningeal metastasis: A solitary presentation of late relapsed invasive lobular breast cancer. ASCO Direct Highlights™ 2019 Miami Symposium, FL.
• Sun J, Guan X, Taylor J, Kumar R, Uddin I, Sequeira C, Ward D, Manoucheri M. An elusive cause of acute anemia in relapsed Waldenstrom Macroglobulinemia confounded by portal hypertensive GI bleeding. Advent Health Graduate Medical Education Research & Quality Improvement Day 2019.
• Tao L, Sun J, Mekhail T, Meng L, Fang C, Du Y, Socinski M, Chang J. The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma. American Society of Clinical Oncology (ASCO) Annual Meeting 2019.
• Sun J, Tao L, Patel RD, Mori S, Chang J. Clinical utility of multiple-gene mutation testing by next-generation sequencing in acute myeloid leukemia in community hospital setting. American Society of Hematology the 60th Annual Meeting and Exposition, 2018. San Diego, CA.
• Sun J, Everett G, Accola K. Thoughts from a rare case of mitral stenosis in a patient with antiphospholipid syndrome. The 16th annual American Medical Association Research Symposium, 2018. National Harbor, MD.
• Tao L, Sun J, Jain A, Ouyang J, Tambunan D. Not all lytic bone lesions created equally – A rare case of Polyostotic fibrous dysplasia involving spine. Florida Medical Association Poster Symposium, 2018. Orlando, FL.
• Sun J, Lee KJ, Chen DJ. Human Mre11 cannot overcome the ability of Ku70/80 to block Exo1-mediated DNA end resection in vitro. Gordon Conference Mammalian DNA Repair 2011. Ventura, CA.
• Sun J, Lee ST, Ko WH, Cheung WT. Receptor activity of GPCR mas is suppressed by C-terminal GFP tagging. American Association for Cancer Research (AACR) Annual Meeting 2008. San Diego, CA.

Journal Club Presentations

• Adjuvant management of high risk stage III dMMR colorectal cancer with BRCA2 and TPM-NTRK1 mutation, 03/2021
• Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia, 11/2021

Book Chapters

• Tumor Board Review, Third Edition, 06/2022. Chapter 5 Hormone Receptor Positive Breast Cancer Case 5.3 Adjuvant targeted therapy - PARP and CDK 4/6 inhibitor in BRCA carrier with residual ER+ disease and 4+ lymph nodes
• Invited to contribute to Overview of Inflammatory Breast Cancer Updates Chapter with the Role of Tumor Microenvironment on Inflammatory Breast Cancer